How would you treat a patient with metastatic NSCLC on pembrolizumab with a sustained complete response, now with 2 isolated small liver lesions?  

I am unaware of any "level 1" evidence for this approach, much of our data is anecdotal, however there is certainly reasonable experience of treating "oligo-progressive" disease with local therapies.  While there is more experience in adrenal and CNS metastatic disease, I would think that a loc...